erenumab (TBC)


Original post, click here

Generic Name: erenumab

Brand Name: TBC

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Migraine

Manufacturer Requested Reimbursement Criteria1:

For the prevention of migraine in adults with at least 8 migraine days per month who have previously failed at least two migraine preventive therapies due to lack of efficacy, intolerance, or clinical contraindication.

Submission Type: New

Project Status: Pending

Call For Patient Input: July 12, 2018

Patient Input Closed: August 31, 2018

Anticipated Date: August 10, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

headache disorders, nervous system